Merck: Keytruda results announced
(CercleFinance.com) - On Saturday Merck and the Canadian Cancer Trials Group (CCTG) announced the results of the phase 3 trial evaluating Keytruda, in combination with chemotherapy, as first-line treatment for patients with unresectable advanced pleural mesothelioma.
The combination significantly improved overall survival, reducing the risk of death by 21% with a median overall survival of 17.3 months compared to 16.1 months for chemotherapy alone.
These late-breaking data were presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting and are being discussed with regulatory authorities around the world.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The combination significantly improved overall survival, reducing the risk of death by 21% with a median overall survival of 17.3 months compared to 16.1 months for chemotherapy alone.
These late-breaking data were presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting and are being discussed with regulatory authorities around the world.
Copyright (c) 2023 CercleFinance.com. All rights reserved.